U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H13O3.Na
Molecular Weight 264.2517
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENOPROFEN SODIUM

SMILES

[Na+].CC(C([O-])=O)C1=CC(OC2=CC=CC=C2)=CC=C1

InChI

InChIKey=WVKIYGXHDKTNFO-UHFFFAOYSA-M
InChI=1S/C15H14O3.Na/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13;/h2-11H,1H3,(H,16,17);/q;+1/p-1

HIDE SMILES / InChI

Description

Fenoprofen is a propionic acid derivative with analgesic, antiinflammatory and antipyretic properties. Fenoprofen inhibits prostaglandin synthesis by decreasing the enzyme needed for biosynthesis. In patients with rheumatoid arthritis, the anti-inflammatory action of fenoprofen has been evidenced by relief of pain, increase in grip strength, and reductions in joint swelling, duration of morning stiffness, and disease activity (as assessed by both the investigator and the patient). In patients with osteoarthritis, the anti-inflammatory and analgesic effects of fenoprofen have been demonstrated by reduction in tenderness as a response to pressure and reductions in night pain, stiffness, swelling, and overall disease activity (as assessed by both the patient and the investigator). These effects have also been demonstrated by relief of pain with motion and at rest and increased range of motion in involved joints. In patients with rheumatoid arthritis and osteoarthritis, clinical studies have shown fenoprofen to be comparable to aspirin in controlling the aforementioned measures of disease activity, but mild gastrointestinal reactions (nausea, dyspepsia) and tinnitus occurred less frequently in patients treated with fenoprofen than in aspirin-treated patients. It is not known whether fenoprofen causes less peptic ulceration than does aspirin. In patients with pain, the analgesic action of fenoprofen has produced a reduction in pain intensity, an increase in pain relief, improvement in total analgesia scores, and a sustained analgesic effect. Indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Also for the relief of mild to moderate pain.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
NALFON
Primary
NALFON
Primary
NALFON

Cmax

ValueDoseCo-administeredAnalytePopulation
28.3 μg/mL
300 mg single, oral
FENOPROFEN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
105.2 μg × h/mL
300 mg single, oral
FENOPROFEN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
300 mg single, oral
FENOPROFEN plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
300 mg single, oral
FENOPROFEN plasma
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer










Drug as perpetrator​

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
400 mg to 600 mg orally 3 or 4 times a day -Maximum dose: 3200 mg/day
Route of Administration: Oral
In Vitro Use Guide
Unknown